Xeris Biopharma announced details for a webinar on XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine injection for hypothyroidism treatment. The webinar will take place on September 9, 2026, at 10 a.m. ET, and will feature a leading endocrinologist and Xeris program team members discussing unmet medical need, market opportunity, and planned Phase 3 development program. Investors can register in advance and access the replay following the event.

Xeris Biopharma

Xeris to Webcast XP-8121 Phase 3 Development Program Overview

Xeris Biopharma Holdings, Inc. is a commercial-stage biotech/pharma company based in Chicago, Illinois. XERS is the ticker symbol for the company's stock. This is the first time the author is covering Xeris Biopharma on Seeking Alpha. The author will provide an investment overview of the company.

Xeris Biopharma: Commercial Stage Pharma With Slow-Burn Buy Opportunity

Xeris Biopharma: Barclays Reiterates Overweight, PT Raised to $12.00 from $9.00.

Barclays

Xeris Biopharma Holdings reported record Q2 revenue of $92.1mln, tightening its 2026 revenue outlook to $385-$390mln. The stock has seen a 33.49% 90-day share price return and a 292.92% three-year total shareholder return. Despite a widening loss, the company's strong revenue guidance and persistent high gross margins set the stage for operational leverage and sustainable EBITDA and net margin improvements.

Xeris Biopharma Posts Record Q2 Revenue, Outlook Tightened

Xeris Biopharma (XERS) shares fell 12.08% in intraday trading after the company reported a significant Q2 2026 GAAP earnings miss of -$0.18 per share, driven by a $31 million non-cash charge from convertible notes exchange. Despite beating revenue estimates and showing strong Recorlev sales growth, the stock declined as the company also tightened its full-year 2026 revenue guidance to $385–$390 million.

XERS News